Objectives:
The present study aimed to investigate the impact of
BRCA1
protein expression on the patients’ outcome of ovarian serous carcinoma, and its correlation with different clinicopathologic features.
Methods:
Immunohistochemistry with
BRCA1
was done for 80 cases of ovarian serous carcinoma that had a positive family history. Correlation with clinico-pathologic variables and patients’ outcomes was investigated.
Results:
BRCA1
expression was detected in 61.2% of the studied cases. A significant relation with patients’ age, tumor grade and tumor stage was found (P<0.05). Also, there was a significant decrease in disease free survival (DFS) & overall survival (OS) in the positive
BRCA1
group. Metastasis, recurrence, residual disease, and mortality rate showed significantly higher figures in patient with
BRCA1
expression (P<0.05).
Conclusion:
Positive
BRCA1
expression had proven to be associated with advanced stage & grade of tumors, as well as worsened prognostic survival parameters (metastasis, recurrence, residual disease, and mortality) in patients with ovarian serous carcinoma.